Latanoprost Actavis

Latanoprost, the active ingredient in Latanoprost Actavis, is a prostaglandin F2α analog presented as a topical ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Latanoprost Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Elevated intra‑ocular pressure (IOP): achieves sustained pressure reduction to protect optic nerve health.

Latanoprost may cause ocular and peri‑ocular reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation change. - Eye irritation: transient burning or stinging sensation.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Macular edema: fluid accumulation in the central retina that can affect vision.

Before initiating therapy, consider the following safety measures. - Monitor intra‑ocular pressure: assess response after the first few weeks. - Assess for ocular inflammation: discontinue if severe uveitis develops. - Avoid use in patients with known hypersensitivity to prostaglandin analogs. - Caution in corneal disease: evaluate corneal health prior to treatment. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analog eye drops: risk of excessive pressure lowering. - Use with ocular prostaglandin‑containing formulations: may increase adverse ocular effects.

Moderate Interactions (Monitor Closely): - Combination with beta‑blocker eye drops: additive IOP‑lowering effect, monitor pressure. - Use with carbonic anhydrase inhibitor eye drops: enhanced pressure reduction, adjust therapy as needed. - Co‑administration with corticosteroid eye drops: possible reduction in Latanoprost efficacy, observe response.